Aortic stenosis -pathogenesis, prediction of progression, and percutaneous intervention Aortic stenosis is common and an important cause of morbidity and mortality. Prevalence will increase signi cantly in forthcoming decades as a function of the ageing population; treatment by means of surgery or percutaneous intervention is expensive. Epidemiological, mechanistic and interventional studies are therefore vital to determine optimal and innovative treatments and their funding.
Introduction aortic stenosis (as), fi rst described in 1663 by lazare riviere who noted left ventricular (lv) enlargement and carunclelike masses obstructing the lv outfl ow tract, 1 is currently the most prevalent native valve pathology in the Western world.
2 the disease is characterised by a bimodal clinical course with an initial long quiescent phase followed by rapid clinical deterioration and high mortality once symptoms such as angina, syncope or heart failure develop. 3 however, more recent studies demonstrate that outcome is worse than previously assumed in patients with mild to moderate as, and that rapid progression to severe stenosis is not uncommon. 4 moreover, even patients with so called 'aortic sclerosis' (initially considered a benign condition) experience signifi cant medical and surgical events over 20 year followup. 5 despite high prevalence and major impact on morbidity and mortality, there is no effective evidence-based medical therapy.
Pathogenesis
as is characterised by progressive aortic valve narrowing and secondary lv hypertrophy. 6 the earliest pathophysiological stages are characterised by endothelial damage, lipid deposition, and infl ammation, and share many similarities with atherosclerosis. subsequent progressive calcifi cation due to increased osteoblast activity within the valve results in leafl et stiffening, reduced separation and valve narrowing. despite promising pre-clinical data, several randomised controlled trials, including the scottish aortic stenosis and lipid lowering trial impact on regression (saltire) study, 1 interventional fellow in valvular heart disease; 2 Professor of interventional Cardiology and valvular heart disease, department of Cardiology, st thomas' hospital, london, uK. have demonstrated that lipid lowering has no impact on the progression of calcifi c as. 7 as a consequence, studies investigating the effects of pharmacological manipulation of calcium pathways in patients with mild and moderate as are now underway.
as increases pressure afterload, resulting in lv wall stress and hypertrophy. the combination of these mechanical forces with insuffi cient myocardial oxygen supply (as a result of increased myocardial mass, afterload and an insuffi cient coronary capillary network) leads to increased apoptosis in the hypertrophied ventricle, 6, [8] [9] [10] [11] fi brosis and scarring with eventual progressive lv dysfunction 12 and rapid clinical deterioration.
Predictors of progression and the timing of intervention
in patients with asymptomatic severe as, guidelines currently recommend close clinical monitoring for the development of symptoms prior to consideration of aortic valve intervention. however, the long-term outcome of conservative management is often poor and these patients may be better served by an earlier interventional strategy. 13 the current challenge is to locate the 'sweet spot', allowing identification of patients on the verge of developing symptoms (or asymptomatic lv decompensation) who will then benefi t from prompt intervention. rosenhak et al. 14 have already demonstrated the value of echocardiography in predicting the outcome of asymptomatic patients with severe as, whereby event-free survival rates were worse for patients with a higher peak aortic jet velocity. more recently, Chin et al. have reported an association of plasma cardiac troponin i (ctni) concentration with advanced hypertrophy and mid-wall myocardial fibrosis, 15, 16 as well as the important clinical endpoints of cardiovascular death or need for aortic valve replacement. as such, it has been suggested that ctni (and other putative biomarkers, such as b-type natriuretic peptide) may play a role in the early recognition of the transition from hypertrophy to heart failure. 17 ,18 the forthcoming evolved-as study will investigate whether a strategy of screening using a combination of chemical, eCg and imaging biomarkers is able to identify at-risk patients with asymptomatic moderate-severe as who will benefi t from early intervention.
Transcatheter aortic valve intervention the number of elderly is growing. the oxvalve population cohort study 19 demonstrated that previously undetected valvular heart disease affects half of the elderly population and predicts a signifi cant rise in the clinical impact of this emerging epidemic, with a projected two-fold increase in prevalence by 2046. although surgical aortic valve replacement (savr) is increasingly performed in the elderly population with severe as, 20, 21 the presence of multiple comorbidities often precludes surgery resulting in systematic undertreatment of this at-risk population. 20, [22] [23] [24] [25] an alternative to savr was therefore warranted. in 2002, Cribier et al. 26 reported the fi rst human case of percutaneous prosthetic aortic valve implantation via the antegrade transseptal approach. the original valve was composed of three bovine pericardial leafl ets mounted within a tubular, stainless steel balloon-expandable stent and the implantation was performed successfully in a 57-year-old male with multiple comorbidities and prohibitive surgical risk. in the wake of this pioneering intervention, a huge volume of research and technical innovation have contributed to the evolution of transcatheter aortic valve intervention (tavi).
the Partner 1 Cohort b randomised controlled trial 27 established that tavi reduced mortality in comparison with medical therapy, while the companion Partner 1 Cohort a study 28 confi rmed equivalent outcomes of tavi and savr in high-risk groups at long-term follow-up. moreover, the Corevalve high-risk trial 29 demonstrated outcomes with transfemoral tavi that surpassed the results of savr; this trend has been observed in other more recent studies. not only have these trials demonstrated the non-inferiority of tavi to savr in high-risk patients, they have indicated superior outcomes with transfemoral tavi. 30 the Partner 2 Cohort a randomised controlled trial 31 compared tavi and savr in intermediate-risk patients with symptomatic severe as. the primary endpoint of all-cause mortality or disabling stroke at two years was similar in the tavi and savr study groups (19.3% vs 21.1%, p = 0.25). importantly, a predefi ned sub-analysis demonstrated a clear advantage of transfemoral tavi over savr (primary endpoint 16.8% vs 20.4%, p = 0.05) with favourable implications for contemporary practice where 90% of tavi is performed via the transfemoral approach. in the parallel Partner s3i study, 32 using the third-generation saPien 3 device, rates of mortality, stroke and at least moderate paravalvular regurgitation were remarkably low at one year (7.4%, 4.6% and 1.5%, respectively) and superior to propensity-matched controls undergoing savr in the Partner 2 Cohort a trial. the notion trial 33 compared tavi and savr in low-risk patients and demonstrated a trend towards reduced mortality in the tavi cohort. Confi rming the role of tavi in younger and lower-risk patients will be addressed more comprehensively by upcoming trials such as Partner 3.
Future direction
tavi has experienced phenomenal growth. between 2007 and 2015, almost 10,000 procedures were performed in the uK. in germany there has been a 20-fold increase in tavi since 2008, from 637 to 13,264 procedures in 2014, surpassing the annual numbers of isolated savr since 2013. 34 tavi is now accessible in more than 65 countries and more than 250,000 implantations have been performed. the increasing popularity of tavi may be attributed in part to the progressive improvement in tavi outcomes. Potential reasons 30 include i) refi nements in valve design leading to reduction in the rate of post-implantation paravalvular regurgitation (which had been associated with inferior outcome), ii) reduced permanent pacemaker requirements as a result of more accurate valve implantation, iii) lower-profi le delivery systems resulting in reduced vascular complications and use of a fully percutaneous transfemoral approach in the majority of patients, iv) adoption of conscious sedation protocols in most centres, 35 thereby avoiding the potential complications of general anaesthesia and facilitating earlier hospital discharge, and v) increasing operator experience.
Conclusion
as is common and causes significant morbidity and mortality. it is an active process, sharing some similarities with atherosclerosis. additional components of importance include calcifi cation of the valve, lv hypertrophy and fi brosis.
Currently, there are no medical therapies that can avert disease progression.
biological markers (such as ctni) and advanced imaging modalities (such as cardiac magnetic resonance) that can demonstrate earliest evidence of lv decompensation may play a role in the timely detection of the transition from hypertrophy to heart failure, enabling prompt intervention.
the burden of as is set to increase with an ageing population and the surgical risk is often prohibitive in such a cohort, especially if accompanied by multiple comorbidities. tavi has already proven to be a comparable (if not superior) alternative to savr in high and intermediate-risk patients. its effectiveness in low-risk patients will be addressed in imminent trials.
